Synonym
BL1249; BL 1249; BL-1249
IUPAC/Chemical Name
5,6,7,8-Tetrahydro-N-[2-(2H-tetrazol-5-yl)phenyl]-1-naphthalenamine
InChi Key
YYNRZIFBTOUICE-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H17N5/c1-2-8-13-12(6-1)7-5-11-15(13)18-16-10-4-3-9-14(16)17-19-21-22-20-17/h3-5,7,9-11,18H,1-2,6,8H2,(H,19,20,21,22)
SMILES Code
C1(NC2=CC=CC=C2C3=NNN=N3)=C4CCCCC4=CC=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
BL-1249 is a nonsteroidal anti-inflammatory drug (NSAID) and a potassium channel activator. BL-1249 potently activates K2P2.1 (TREK-1) and K2P10.1 (TREK-2) with EC50 values of 5.5 μM and 8.0 μM, respectively.
In vitro activity:
BL-1249 also produced a membrane hyperpolarization of acutely dissociated rat bladder myocytes. Voltage-clamp studies in human bladder cells revealed that BL-1249 activated an instantaneous, noninactivating current that reversed near E(K).
Reference: J Pharmacol Exp Ther. 2005 Apr;313(1):250-9. https://pubmed.ncbi.nlm.nih.gov/15608074/
In vivo activity:
Local peripheral or intrathecal pre-treatment with BL-1249, selective opener of TREK-1, decreased long-lasting secondary mechanical allodynia and hyperalgesia induced by formalin. Pre-treatment with BL-1249 prevented the pro-nociceptive effect of spadin on acute nociception and long-lasting mechanical allodynia and hyperalgesia in rats.
Reference: Behav Brain Res. 2021 Jul 3;413:113446. https://pubmed.ncbi.nlm.nih.gov/34224765/
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMSO |
29.1 |
100.01 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
291.36
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Tertyshnikova S, Knox RJ, Plym MJ, Thalody G, Griffin C, Neelands T, Harden DG, Signor L, Weaver D, Myers RA, Lodge NJ. BL-1249 [(5,6,7,8-tetrahydro-naphthalen-1-yl)-[2-(1H-tetrazol-5-yl)-phenyl]-amine]: a putative potassium channel opener with bladder-relaxant properties. J Pharmacol Exp Ther. 2005 Apr;313(1):250-9. doi: 10.1124/jpet.104.078592. Epub 2004 Dec 17. PMID: 15608074.
2. García G, Martínez-Rojas VA, Murbartián J. TREK-1 potassium channels participate in acute and long-lasting nociceptive hypersensitivity induced by formalin in rats. Behav Brain Res. 2021 Jul 3;413:113446. doi: 10.1016/j.bbr.2021.113446. Epub ahead of print. PMID: 34224765.
3. García G, Méndez-Reséndiz KA, Oviedo N, Murbartián J. PKC- and PKA-dependent phosphorylation modulates TREK-1 function in naïve and neuropathic rats. J Neurochem. 2021 Jun;157(6):2039-2054. doi: 10.1111/jnc.15204. Epub 2020 Oct 19. PMID: 33006141.
In vitro protocol:
1. Tertyshnikova S, Knox RJ, Plym MJ, Thalody G, Griffin C, Neelands T, Harden DG, Signor L, Weaver D, Myers RA, Lodge NJ. BL-1249 [(5,6,7,8-tetrahydro-naphthalen-1-yl)-[2-(1H-tetrazol-5-yl)-phenyl]-amine]: a putative potassium channel opener with bladder-relaxant properties. J Pharmacol Exp Ther. 2005 Apr;313(1):250-9. doi: 10.1124/jpet.104.078592. Epub 2004 Dec 17. PMID: 15608074.
In vivo protocol:
1. García G, Martínez-Rojas VA, Murbartián J. TREK-1 potassium channels participate in acute and long-lasting nociceptive hypersensitivity induced by formalin in rats. Behav Brain Res. 2021 Jul 3;413:113446. doi: 10.1016/j.bbr.2021.113446. Epub ahead of print. PMID: 34224765.
2. García G, Méndez-Reséndiz KA, Oviedo N, Murbartián J. PKC- and PKA-dependent phosphorylation modulates TREK-1 function in naïve and neuropathic rats. J Neurochem. 2021 Jun;157(6):2039-2054. doi: 10.1111/jnc.15204. Epub 2020 Oct 19. PMID: 33006141.
1: Pope L, Arrigoni C, Lou H, Bryant C, Gallardo-Godoy A, Renslo AR, Minor DL Jr. Protein and Chemical Determinants of BL-1249 Action and Selectivity for K(2P) Channels. ACS Chem Neurosci. 2018 Aug 22. doi: 10.1021/acschemneuro.8b00337. [Epub ahead of print] PubMed PMID: 30089357; PubMed Central PMCID: PMC6302903.
2: Ma R, Seifi M, Papanikolaou M, Brown JF, Swinny JD, Lewis A. TREK-1 Channel Expression in Smooth Muscle as a Target for Regulating Murine Intestinal Contractility: Therapeutic Implications for Motility Disorders. Front Physiol. 2018 Mar 6;9:157. doi: 10.3389/fphys.2018.00157. eCollection 2018. PubMed PMID: 29563879; PubMed Central PMCID: PMC5845753.
3: Veale EL, Al-Moubarak E, Bajaria N, Omoto K, Cao L, Tucker SJ, Stevens EB, Mathie A. Influence of the N terminus on the biophysical properties and pharmacology of TREK1 potassium channels. Mol Pharmacol. 2014 May;85(5):671-81. doi: 10.1124/mol.113.091199. Epub 2014 Feb 7. PubMed PMID: 24509840.
4: Tertyshnikova S, Knox RJ, Plym MJ, Thalody G, Griffin C, Neelands T, Harden DG, Signor L, Weaver D, Myers RA, Lodge NJ. BL-1249 [(5,6,7,8-tetrahydro-naphthalen-1-yl)-[2-(1H-tetrazol-5-yl)-phenyl]-amine]: a putative potassium channel opener with bladder-relaxant properties. J Pharmacol Exp Ther. 2005 Apr;313(1):250-9. Epub 2004 Dec 17. PubMed PMID: 15608074.
